BioCryst Pharmaceuticals
BCRX
234 hedge funds and large institutions have $1.87B invested in BioCryst Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 76 increasing their positions, 59 reducing their positions, and 26 closing their positions.
201% more call options, than puts
Call options by funds: $54.3M | Put options by funds: $18M
62% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 26
29% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 59
17% more capital invested
Capital invested by funds: $1.61B → $1.87B (+$267M)
6% more funds holding
Funds holding: 221 → 234 (+13)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
1.9% less ownership
Funds ownership: 81.83% → 79.93% (-1.9%)
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$32.8M |
| 2 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$18.2M |
| 3 |
Two Sigma Investments
New York
|
+$10.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.68M |
| 5 |
D.E. Shaw & Co
New York
|
+$6.38M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$44.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$20.6M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$15.9M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$13.4M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$11.7M |
BCRX Hedge Fund Activity: Q3 2022 in Review
234 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2022, worth a combined $1.87B — up 17% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new BCRX positions and 26 closed out — a net gain of 16 holders — while 76 added to existing stakes and 59 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $32.8M. The largest seller was Morgan Stanley, cutting an estimated $44.6M.
- 234 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2022, up from 221 in Q2 2022.
- Funds reported $1.87B of BioCryst Pharmaceuticals stock for Q3 2022, up 17% quarter-over-quarter.
- 42 funds opened new BioCryst Pharmaceuticals positions in Q3 2022 and 26 closed out, a net change of +16 holders.
- The largest BioCryst Pharmaceuticals buyer in Q3 2022 was Avoro Capital Advisors, an estimated $32.8M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2022 was Morgan Stanley, an estimated $44.6M sold.
Based on aggregated 13F filings for Q3 2022.